de Kam Digna, Nonnekes Jorik, Oude Nijhuis Lars B, Geurts Alexander C H, Bloem Bastiaan R, Weerdesteyn Vivian
Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Po Box 9101, 6500 HB, Nijmegen, The Netherlands,
J Neurol. 2014 Dec;261(12):2330-7. doi: 10.1007/s00415-014-7496-3. Epub 2014 Sep 17.
In this study, we investigated the effect of dopaminergic medication on reactive stepping responses to forward and backward balance perturbations in patients with moderately severe Parkinson's disease (PD). Twelve PD patients, Hoehn and Yahr stage ranging from 2 to 3, and 15 healthy controls were exposed to multidirectional translational stance perturbations on a moveable platform. Perturbations were unpredictable in terms of amplitude, timing and direction. Patients were tested in the medication ON and OFF (at least 12 h of dopaminergic medication withdrawal) state on two separate days. Forward and backward stepping responses were quantified in terms of (1) presence, onset and amplitude of anticipatory postural adjustments (APAs); (2) spatiotemporal step variables (step onset, length and velocity); and (3) leg inclination angle at first stepping-foot contact. When perturbed forward, patients performed worse than controls in terms of step length (0.32 ± 0.07 vs. 0.38 ± 0.05 m, p = 0.01) and step velocity (1.21 ± 0.16 vs. 1.37 ± 0.13 m/s, p = 0.01), while step onset was not different. The number of steps with an APA was larger in patients in the OFF state than in controls which was, however, only significant after forward perturbations (43 vs. 20%, p = 0.01). Following backward perturbations, leg angles at foot contact were smaller in patients compared to controls (-2.71° ± 4.29° vs. 0.26° ± 2.80°, p = 0.04) reflecting a poorer mechanical efficiency of the step. Dopaminergic medication had no significant effect on any of these outcomes. In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.
在本研究中,我们调查了多巴胺能药物对中度严重帕金森病(PD)患者对向前和向后平衡扰动的反应性迈步反应的影响。12例Hoehn和Yahr分期为2至3期的PD患者以及15名健康对照者在可移动平台上接受多方向平移姿势扰动。扰动在幅度、时间和方向方面不可预测。患者在两个不同的日子分别在服药和停药(至少停用多巴胺能药物12小时)状态下进行测试。向前和向后迈步反应通过以下方面进行量化:(1)预期姿势调整(APA)的存在、起始和幅度;(2)时空步长变量(步长起始、长度和速度);以及(3)第一步脚接触时的腿部倾斜角度。向前扰动时,患者在步长(0.32±0.07 vs. 0.38±0.05米,p = 0.01)和步速(1.21±0.16 vs. 1.37±0.13米/秒,p = 0.01)方面比对照者表现更差,而步长起始无差异。停药状态下患者有APA的步数比对照者多,然而,仅在向前扰动后有显著差异(43% vs. 20%,p = 0.01)。向后扰动后,患者脚接触时的腿部角度比对照者小(-2.71°±4.29° vs. 0.26°±2.80°,p = 0.0